• Brefeldin A Workflows for ER Stress Research

  2026-09-15

  Brefeldin A converts a trafficking perturbation into a practical way to study ER stress, secretion defects, and cell-fate decisions in parallel. This workflow shows how BFA can distinguish transport-dependent phenotypes from downstream apoptosis while improving assay reproducibility in cancer and cell-biology models.

• Filipin III for Membrane Cholesterol Detection

  2026-09-15

  Filipin III is a polyene macrolide antibiotic used for cholesterol detection in membranes and membrane cholesterol visualization. Its cholesterol-dependent aggregation, fluorescence decrease, and sterol-selective vesicle lysis make it useful for localization studies, but not a standalone quantitative assay for oxysterol signaling.

• Brefeldin A Workflows for ER Stress and Trafficking

  2026-09-14

  Brefeldin A (BFA) gives researchers a controllable way to perturb ER-to-Golgi trafficking, secretion, ER stress, and cancer-cell survival in the same experimental framework. This guide translates the compound’s mechanism into practical workflows, including endothelial-assay safeguards inspired by a sepsis biomarker study.

• LY2109761: Dual TGF-β Receptor Kinase Inhibitor

  2026-09-14

  LY2109761 is a TGF-β receptor type I and II dual inhibitor that competitively targets the ATP-binding site of TβRI kinase. Product information reports nanomolar kinase potency and preclinical activity in pancreatic cancer, glioblastoma, bone-tumor, and fibrosis models, while the cited GBM study supports the biological importance of Smad-dependent signaling rather than direct clinical efficacy.

• SW033291: A Practical 15-PGDH Workflow

  2026-09-13

  SW033291 turns 15-PGDH inhibition into a measurable workflow spanning PGE2 assays, hematopoietic models, and muscle regeneration research. This guide connects biochemical potency with experimental design, combination studies, and troubleshooting for semaglutide-associated muscle recovery models.

• Triple-Pathway Inhibition in BRAFV600E Melanoma

  2026-09-12

  The reference study shows that RocA-induced stress in BRAFV600E melanoma activates temporally distinct ERK1/2–EZH2 and AKT1–eIF4E resistance programs. Its central practical finding is that concurrent inhibition of eIF4F, EZH2, and AKT1 can improve responses in RocA- and vemurafenib-resistant models, although the evidence remains preclinical and melanoma-specific.

• Nav1.6–NHE1 Signaling in Glioblastoma

  2026-09-11

  A 2025 Molecular Biology Reports study identifies a functional Nav1.6–NHE1 axis that supports glioblastoma proliferation and migration while sustaining ERK-AKT survival signaling. Its combined genetic and pharmacological design links ion regulation with measurable changes in DNA synthesis, motility, and apoptosis, although validation beyond cultured cell models is still needed.

• Exosomal HMGB1 in Lupus Nephritis Endothelial Injury

  2026-09-11

  The reference study identifies podocyte-derived exosomal HMGB1 as a mechanistic driver of glomerular endothelial cell injury in lupus nephritis through TRIM27 upregulation. Its combined patient, cell, and mouse experiments support exosome release and HMGB1 cargo as experimentally tractable points for dissecting podocyte–endothelial communication.

• Imipenem: Mechanism and Research Applications

  2026-09-10

  Imipenem is a semisynthetic thienamycin antibiotic with broad-spectrum activity against gram-negative and gram-positive bacteria. Its PBP-directed cell-wall mechanism, defined research concentrations, and sepsis animal model findings support antibacterial research while remaining distinct from clinical efficacy claims.

• MK-8745: Reading Aurora A Dependency in Cancer

  2026-09-10

  MK-8745 is a potent, selective Aurora A inhibitor for connecting mitotic disruption with apoptosis and tumor biology. This article uses retinoblastoma evidence to show how target expression, functional dependency, and assay phenotype should be interpreted together.

• Azilsartan (TAK-536) Experimental Workflows

  2026-09-09

  Azilsartan (TAK-536) provides a selective AT1-receptor perturbation strategy for separating renin–angiotensin signaling from broader inflammatory effects. This guide translates reactive astrocyte–microglia findings into practical dosing, controls, readouts, and troubleshooting steps for cardiovascular and neuroinflammation research.

• Angiotensin II Workflows for AAA Research

  2026-09-09

  Build reproducible hypertension, vascular remodeling, and abdominal aortic aneurysm workflows with a defined Angiotensin II stimulus. This guide connects acute receptor signaling and vascular smooth muscle phenotypes with the senescence-gene framework reported in recent AAA research, while separating validated parameters from practical assay recommendations.

• KR-12 Human Antimicrobial Peptide: Bench Workflows

  2026-09-08

  KR-12 combines membrane-targeted antimicrobial activity with anti-biofilm, LPS-neutralizing, and host-response applications in a compact LL-37 fragment. This practical guide covers TFA-salt handling, strain-aware assays, biofilm testing, mammalian-cell controls, copper-variable experiments, and troubleshooting strategies.

• Haloprogin: Applied Antifungal Research Workflows

  2026-09-08

  Haloprogin supports quantitative workflows spanning dermatophyte, Candida, and selected Gram-positive bacterial assays. This guide translates historical MIC/MFC methods and topical infection-model findings into practical setup, formulation, comparison, and troubleshooting decisions.

• Bufalin–STK33 Degradation in Triple-Negative Breast Cancer

  2026-09-07

  The reference study identifies STK33 as a Bufalin-binding protein and connects its destabilization to reduced triple-negative breast cancer growth. By combining target-discovery chemistry, mechanistic protein analyses, animal models, and patient-derived organoids, the work provides a preclinical framework for target-based TNBC research while leaving clinical selectivity and safety unresolved.

8647 records 7/577 page Previous Next First page 上5页 678910 下5页 Last page